Social media

For #NationalImmunisationAwarenessMonth our blog looks at the recent history and the future of vaccines. Vaccine developers have an active role to play in supporting individuals and physicians to make informed decisions ...

If you would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter. https://ow.ly/jY7C50WwH5E Compiled and collated by ICON’s Regulatory Intelligence Team and de...

Multi-indication development strategies help increase a drug candidate's overall value, but remain complex and increasingly expensive, requiring significant clinical, administrative and site monitoring costs. Learn how d...

Delphi panels are a powerful way to gather expert consensus and patient insights—but designing them isn’t always straightforward. ICON’s experts explain how to tailor Delphi panel designs to meet your research goals. Le...

Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse a...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

Join ICON at the #SCDM 2025 South Africa Single Day Event on 22 August in Bloemfontein. Madelie Gerber will present on regulatory updates, offering perspectives on their impact on data management, while Marike Brandt wil...

As the Asia-Pacific (APAC) region continues to emerge as a key player in the biosimilar sector, it presents significant opportunity for market entry and expansion. In our latest blog on this region, we explore critical...

With no universal standard, designing Delphi panels can be complex—but also incredibly valuable. ICON’s Patient-Centred Outcomes experts share practical strategies for tailoring Delphi designs to support expert consensus...

Multi-indication development is now central to cardiometabolic drug pipelines. A 2025 ICON survey shows 83% of developers engage in multi-indication therapies. What commercialisation strategies are they employing? Explor...